New Treatment for Pulmonary Fibrosis - Submission of Medical Endpoints to the FDA

EmphyCorp Press Release

New Treatment for Pulmonary Fibrosis to improve Patient Quality of Life

EmphyCorp is proud to announce the completion of two clinical trials with our nasal spray, to define medical endpoints as requested by the FDA for the NDA marketing application in patients with pulmonary Fibrosis, under its Orphan Drug Designations for the treatment of Interstitial Lung Diseases (ILD), which includes Pulmonary Fibrosis and Cystic Fibrosis. 

Our Products

Please see "Our Products" Tab on the Home Page